Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model

European Journal of Pharmacology

Volumn 685, Issue 1-3, 2012, Pages 141-148

  Kwak, Hyun Jeong ^a   Nam, Ji Yeon ^b   Song, Jin Sook ^a   No, Zaesung ^b   Yang, Sung Don ^a   Cheon, Hyae Gyeong ^a,c  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Institute Pasteur Korea   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Airway hyperreactivity; Asthma; cAMP; Emesis; PDE 4

Indexed keywords

3 [1 (3 CYCLOPROPYLMETHOXY 4 DIFLUOROMETHOXYBENXYL) 1H PYRAZOL 3 YL]BENZOIC ACID; ANTIASTHMATIC AGENT; EOSINOPHIL PEROXIDASE; LIPOPOLYSACCHARIDE; METHACHOLINE; OVALBUMIN; PDE 423; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HISTOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY;

EID: 84861341040     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.04.016     Document Type: Article

References (44)

1. Barnes, P.J., 1996. Pathophysiology of asthma. Br. J. Clin. Pharmacol. 42, 3-10.
2. Barnes, P.J., Pedersen, S., 1993. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am. Rev. Respir. Dis. 148, S1-S26.
3. Barnette, M.S., 1999. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). In: Jucker, E. (Ed.), Progress in Drug Research, 53. Birkhauser Verlag, Basel, Switzerland.
4. Barnette, M.S., Bartus, J.O., Burman, M., Christensen, S.B., Cieslinski, L.B., Esser, K.M., Prabhakar, U.S., Rush, J.A., Torphy, T.J., 1996. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. 51, 949-956.
5. Bateman, E.D., Boushey, H.A., Bousquet, J., Busse, W.W., Clark, T.J.H., Pauwels, R.A., 2004. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 170, 836-844.
6. Bochner, B.S., Undem, B.J., Lichtenstein, L.M., 1994. Immunological aspects of allergic asthma. Annu. Rev. Immunol. 12, 295-335.
7. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
8. Bundschuh, D.S., Eltze, M., Barsig, J., Wollin, L., Hatzelmann, A., Beume, R., 2001. In vivo efficacy in airway diseasemodels of roflumilast, a novel orally active PDE-4 inhibitor. J. Pharmacol. Exp. Ther. 297, 280-290.
9. Burnouf, C., Pruniaux, M.P., 2002. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Des. 8, 1255-1296.
10. Christensen, S.B., DeWolf Jr. W.E., Ryan, M.D., Torphy, T.J., 1996.Molecular aspects of inhibitor interaction with PDE4. In: Schudt, C., Dent, C., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors. Academic Press, San Diego, pp. 185-207.
11. Conti, M., Jin, S.L.C., 2000. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63, 1-38.
12. Crocker, C., Church, M.K., Ohia, S.E., Townley, R.G., 2000. Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes. Int. Arch. Allergy Immunol. 121, 151-160.
13. Dent, G., Giembycz, M.A., Rabe, K.F., Narnes, P.J., 1991. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by type IC-selective PDE inhibitors. Br. J. Pharmacol. 103, 1339-1346.
14. Draheim, R., Egerland, U., Rundfeldt, C., 2004. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid- 4-yl)-[1[(4-fluorobenzyl)-5- hydroxy-indole-3-yl]-glyoxylic acid amide (AWD12-281), in human cell preparations. J. Pharmacol. Exp. Ther. 308, 555-563.
15. Essayan, D.M., Huang, S.K., Kagey-Sobotka, A., Lichtenstein, L.M., 1997. Differential efficacy of lymphocyte andmonocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99, 28-37.
16. European Medicines Agency, 2010. Product Information. EPAR, Daxas.
17. Fabbri, L.M., Beghé, B., Yasothan, U., Kirkpatrick, P., 2010. Roflumilast. Nat. Rev. Drug Discov. 9, 761-762.
18. Gantner, F., Schudt, C., Wendel, A., Hatzelmann, A., 1999. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm. Pharmacol. Ther. 12, 377-386.
19. Giembycz, M.A., 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma; where are we now and where do we go from here? Drugs 59, 193-212.
20. Hamelmann, E., Schwarze, J., Takeda, K., Oshiba, A., Larsen, G.L., Irwin, C.G., Gelfand, E.W., 1997. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 156, 766-775.
21. Hansen, G., Jin, S., Umetsu, D.T., Conti, M., 2000. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl Acad. Sci. USA 97, 6751-6756.
22. Harbinson, P.L., Macleod, D., Hawksworth, R., O'Toole, S., Sullivan, P.J., Heath, P., Kilfeather, S.M., Page, C.P., Costello, H., Holgate, S.T., 1997. The effect of a novel orally active selective PDE-4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10, 1008-1014.
23. Hatzelmann, A., Schudt, C., 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297, 267-279.
24. Kwak, H.J., Song, J.S., No, Z.S., Song, J.H., Yang, S.D., Cheon, H.G., 2005. The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in Raw264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide. Inflamm. Res. 54, 508-513.
25. Kwak, H.J., Song, J.S., Heo, J.Y., Yang, S.D., Nam, J.Y., Cho, Y.S., Cheon, H.G., 2008. Protective effects of pyrrolidine dithiocarbamate against airway inflammation in the ovalbumin-induced mouse model. Eur. J. Pharmacol. 590, 355-362.
26. Lamontagne, S., Meadows, E., Luk, P., Normandin, D., Muise, E., Boulet, L., Pon, D.J., Robichaud, A., Robertson, G.S., Metters, K.M., Nantel, F., 2001. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920, 84-96.
27. Lee, J.J., Dimina, D., Macias, M.P., Ochkur, S.I., McGarry, M.P., O'Neill, K.R., Protheroe, C., Pero, R., Nguyen, T., Cormier, S.A., Lenkiewicz, E., Colbert, D., Rinaldi, L., Ackerman, S.J., Irwin, C.G., Lee, N.A., 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305, 1773-1776.
28. Leonard, E.J., Skeel, A., Yoshimura, T., Noer, K., Kutvirt, S., Epps, D.V., 1990. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. J. Immunol. 144, 1323-1330.
29. Loughney, K., Martins, T.J., Harris, E.A.S., Sadhu, K., Hicks, J., Sonnenburg, W.K., Beavo, J.A., Ferguson, K., 1996. Isolation and characterization of cDNAs corresponding to two human calcium calmodulin-regulated 3,5-cyclic nucleotide phosphodiesterases. J. Biol. Chem. 271, 796-806.
30. Markewitz, B.A., Owens, M.W., Payne, D.K., 1999. The pathogenesis of chronic obstructive pulmonary disease. Am. J. Med. Sci. 318, 74-78.
31. Mue, S., Ise, T., Shibahara, S., Takahashi, M., Ono, Y., 1976. Leukocyte cyclic-3?,5?- nucleotide phosphodiesterase activity in human bronchial asthma. Ann. Allergy 37, 201-207.
32. Ohkawara, Y., Yamauchi, K., Tanno, Y., Tamura, G., Ohtani, H., Nagura, H., Ohkuda, K., Takishima, T., 1992. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am. J. Respir. Cell Mol. Biol. 7, 385-392.
33. Perez-Torres, S., Miro, X., Palacios, J.M., Cortes, R., Puigdomenech, P., Mengod, G., 2000. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 20, 349-374.
34. Robichaud, A., Tattersall, F.D., Choudhury, I., Rodger, I.W., 1999. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38, 289-297.
35. Robichaud, A., Savioe, C., Stamatiou, P.B., Tattersall, F.D., Chan, C.C., 2001. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40, 262-269.
36. Robichaud, A., Savoie, C., Stamatiou, P.B., Lachance, N., Jolicoeur, P., Rasori, R., Chan, C.C., 2002a. Assessing the emetic potential of PDE-4 inhibitors in rats. Br. J. Pharmacol. 135, 113-118.
37. Robichaud, A., Stamatiou, P.B., Jin, S.L., Lachance, N., MacDonald, D., Laliberte, F., Liu, S., Huang, Z., Conti, M., Chan, C.C., 2002b. Deletion of phosphodiesterase 4D in mice shortens ?2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110, 1045-1052.
38. Schneider, H.H., Schmiechen, R., Brezinski, M., Seidler, J., 1986. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127, 105-115.
39. Stockley, R.A., 1996. Cellular mechanisms in the pathogenesis of COPD. Eur. Respir. Rev. 6, 264-269.
40. Taylor, D.R., Bateman, E.D., Boulet, L.P., Boushey, H.A., Busse, W.W., Casale, T.B., 2008. A new perspective on concepts of asthma severity and control. Eur. Respir. J. 32, 545-554.
41. Tenor, H., Hatzelmann, A., Kupferschmidt, R., Stanciu, L., Djukanovic, R., Schudt, C., Wendel, A., Church, M.K., Shute, J.K., 1996. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25, 625-633.
42. Tenor, H., Schudt, C., 1996. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In: Schudt, C., Dent, G., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors. Academic Press, San Diego, pp. 21-40.
43. Torphy, T.J., 1998. Phosphodiesterase isoenzymes - molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157, 351-370.
44. Zao, Y., Zhang, H.T., O'Donnell, J.M., 2003. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J. Pharmacol. Exp. Ther. 305, 565-572.